SCHEMBL31474052

SCHEMBL31474052

COC(=O)c1ccc(Br)c(O)c1F

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA1 P00915 3/20 0.44
CA2 P00918 3/20 0.44
CA9 Q16790 3/20 0.44
CA12 O43570 2/20 0.44
CA7 P43166 2/20 0.44
CA14 Q9ULX7 2/20 0.44
PDK2 Q15119 1/20 0.44
PDK4 Q16654 1/20 0.44
SOS1 Q07889 1/20 0.44
LMNA P02545 1/20 0.43
TSHR P16473 1/20 0.43
GAA P10253 3/20 0.42
MYC P01106 1/20 0.41
MAPT P10636 2/20 0.40
MITF O75030 1/20 0.40
SMN1; SMN2 Q16637 2/20 0.39
SLC6A3 Q01959 2/20 0.39
SLC6A4 P31645 1/20 0.39
NPC1 O15118 1/20 0.39
CASP3 P42574 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20562294 0.86 CA1 (0.44) CA1CA2CA9CA12CA7
SCHEMBL17128958 0.85 SOS1 (0.46) CA1CA2CA9CA12CA7
SCHEMBL29265618 0.83 CA1 (0.48) CA1CA2CA9CA12CA7
SCHEMBL16035010 0.82 SOS1 (0.44) CA1CA2CA9CA12CA7
SCHEMBL23501047 0.81 CA12 (0.52) CA1CA2CA9CA12CA7
SCHEMBL15201401 0.81 CA1 (0.47) CA1CA2CA9CA12CA7
SCHEMBL7502756 0.81 ABL1 (0.47) CA1CA2CA9CA12CA7
SCHEMBL3585020 0.81 SOS1 (0.43) CA1CA2CA9CA12CA7
SCHEMBL17711410 0.81 ABL1 (0.44) CA1CA2CA9CA12CA7
SCHEMBL24928886 0.81 KDM4E (0.45) CA1CA2CA9CA12CA7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250122212-A1 NOVEL COMPOUNDS SITRYX THERAPEUTICS LIMITED (GB) 2025-04-17 US disclosed
WO-2025078808-A1 NOVEL COMPOUNDS SITRYX THERAPEUTICS LIMITED (GB) 2025-04-17 WO disclosed
WO-2025061148-A1 HETEROARYL COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF IN MEDICINE 江苏恒瑞医药股份有限公司 2025-03-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250122212-A1 NOVEL COMPOUNDS CYP11B1, CYP11B2, UGT1A1 CA1 1755/4885CA2 3686/4885CA9 1172/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.